Older adults with type 2 diabetes who used GLP-1 receptor agonists had a 42% lower risk of developing dementia compared to those taking DPP-4 inhibitors.
42% lower dementia riskGLP-1RA users had significantly reduced dementia incidence compared to DPP-4 inhibitor users across 134 healthcare organizations worldwide.
What the researchers found
GLP-1RA use was associated with a 42% lower risk of dementia compared to DPP-4 inhibitors (HR 0.58, 95% CI 0.55–0.61, P < .0001). The drugs were also linked to a 38% lower risk of Alzheimer's disease (HR 0.62) and a 38% lower risk of vascular dementia (HR 0.62). Patients on GLP-1RAs were 24% less likely to be prescribed dementia-related medications (HR 0.76). These risk reductions were consistent across subgroups stratified by age, sex, and specific GLP-1RA type.
Why it matters
With dementia rates rising globally and no cure available, finding that a widely prescribed diabetes medication class may substantially reduce dementia risk could have enormous public health implications. If confirmed in randomized trials, this could reshape how clinicians choose diabetes treatments for older adults.
How the study worked
This was a retrospective cohort study using electronic health records from 134 healthcare organizations worldwide via the TriNetX network. Researchers used an active-comparator, new-user design with 1:1 propensity score matching to compare 82,689 GLP-1RA users with 82,689 DPP-4i users aged 65+ with type 2 diabetes. Cox proportional hazards models estimated dementia risk.
What this study cannot tell us
As a retrospective observational study, it cannot establish causation — unmeasured confounders may explain the association. The use of electronic health records means some dementia cases may be underdiagnosed or miscoded. The comparison was against DPP-4 inhibitors specifically, not a placebo, so the results reflect relative rather than absolute risk reduction. Follow-up duration was not specified.
How to read the evidence
This is a large, well-designed retrospective cohort study with propensity score matching and robust sensitivity analyses. While it provides strong observational evidence, it cannot establish causation. Randomized controlled trials are needed for definitive conclusions.
When this study was published
Published in 2025 using data through November 2024, this is one of the most current and largest studies examining GLP-1RAs and dementia risk.
The bigger picture
This study adds to a growing body of evidence suggesting GLP-1 receptor agonists have neuroprotective effects beyond their metabolic benefits. The consistency of the findings across dementia subtypes and patient subgroups strengthens the case for potential brain-protective properties of these peptide-based drugs, though the mechanisms remain to be fully understood.
Questions still open
- What biological mechanisms might explain the neuroprotective effects of GLP-1 receptor agonists?
- Would randomized controlled trials confirm these observational findings?
- Do GLP-1RAs also reduce dementia risk in people without diabetes?
Common questions
Can GLP-1 weight-loss drugs like Ozempic prevent dementia?
Should older adults switch to GLP-1 receptor agonists to protect their brain health?
Read the original research
Glucagon-Like Peptide-1 Receptor Agonists and Dementia Risk Reduction in Older Adults With Type 2 Diabetes: A Retrospective Cohort Study.
Journal of the American Medical Directors Association, 26(12), 105901
Citation
Wu, Jheng-Yan; Lin, Yu-Min; Hsu, Wan-Hsuan; Liu, Ting-Hui; Tsai, Ya-Wen; Huang, Po-Yu; Chuang, Min-Hsiang; Yu, Tsung; Lai, Chih-Cheng. (2025). Glucagon-Like Peptide-1 Receptor Agonists and Dementia Risk Reduction in Older Adults With Type 2 Diabetes: A Retrospective Cohort Study.. Journal of the American Medical Directors Association, 26(12), 105901. https://doi.org/10.1016/j.jamda.2025.105901